Investigation of the usefulness of Oxidative stress-Responsive Apoptosis Inducing Protein (ORAIP) as a biomarker for inflammatory bowel disease (IBD)

Validation of the usefulness of ORAIP as an IBD biomarker - ORAIP biomarker study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047496

Enrollment

Registered

2022-04-30

Start date

2022-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory bowel disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients who meet the following conditions will be included. (1) Patients with inflammatory bowel disease (mild to severe) 2) Adult (3) Any gender (4)Both inpatients and outpatients are included. (5) Patients who have given their free and voluntary consent to participate in this study.

Exclusion criteria

Exclusion criteria: The following patients will be excluded from the standpoint of ensuring safety. (1) All patients with hepatic disease, renal disease, cardiac disease, or other serious complications that are judged to be inappropriate by the physician in charge. (2) Patients with other autoimmune diseases 2) Patients with other autoimmune diseases. 3) Patients taking antithrombotic medication (3) Patients taking anti-thrombotic drugs (4) Lactating mothers, pregnant women, and those who may be pregnant (5) Other patients deemed unsuitable by the physician. Translated with www.DeepL.com/Translator (free version)

Design outcomes

Primary

Measure	Time frame
Correlation between disease activity and blood ORAIP levels	—

Countries

Japan

Contacts

Public ContactTomoyoshi Shibuya

Juntendo University Gastroenterology

tomoyosi@juntendo.ac.jp03-3813-3111

Outcome results